Clinical Professor of Medicine
UCSF Medical Center
San Francisco, California
Dr Martin is a Clinical Professor of Medicine and Interim Chief the Division of Hematology/Oncology, Director of the Hematologic Malignancies Research Site Committee, Co-Director of the Myeloma Program and Co-Lead for the Hematologic Malignancies Research Program in the Helen Dillier Family Comprehensive Cancer Center at the University of California, San Francisco. Dr Martin has authored many artciles in hematologic malignancies and has been a thought leader and an invited speaker at national and international meetings. He been actively involved in clinical research and has been principal investigator (PI) on over 25 clinical trials. Dr Martin has supervised the multiple myeloma (MM) tissue bank at UCSF since it’s inception in 2009, and this biobank has been utilized for biomarker discovery.
Dr Martin’s main research interests are the development and evaluation of novel therapeutics for multiple myeloma. Most recently, he has been involved in the clinical development of a novel anti-CD38 monoclonal antibody, isatuximab. Dr Martin has lead several Phase I single agent and combination trials with Isatuximab. Investigators at UCSF have found a potential relationship between specific HLA and KIR genotypes and improved response and further studies are ongoing. Dr. Martin continues to be active in immunotherapy trials including antibody-drug conjugate trials, dual targeted antibody trials and cellular therapy trials in relapsed MM.